Abstract
Chemokines are a large group of low molecular weight cytokines that are known to selectively attract and activate different cell types. Although the primary function of chemokines is well recognized as leukocyte attractants, recent evidences indicate that they also play a role in number of tumor-related processes, such as growth, angiogenesis and metastasis. Chemokines activate cells through cell surface seven trans-membranes, G-protein-coupled receptors (GPCR). The role played by chemokines and their receptors in tumor pathophysiology is complex as some chemokines favor tumor growth and metastasis, while others may enhance anti-tumor immunity. These diverse functions of chemokines establish them as key mediators between the tumor cells and their microenvironment and play critical role in tumor progression and metastasis. In this review, we present some of the recent advances in chemokine research with special emphasis on its role in tumor angiogenesis and metastasis.
Similar content being viewed by others
References
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: The ‘seed and soil–hypothesis revisited. Nature Review Cancer, 3(6), 453–58.
Locati, M., Otero, K., Schioppa, T., Signorelli, P., Perrier, P., & Baviera, S., et al. (2002). The chemokine system: Tuning and shaping by regulation of receptor expression and coupling in polarized responses. Allergy, 57(11), 972–82.
Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., & Matsushima, K., et al. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews, 52(1), 145–76.
Zlotnik, A., & Yoshie, O. (2000). Chemokines: a new classification system and their role in immunity. Immunity, 12(2), 121–27.
Murphy, P. M. (2002). International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacological Reviews, 54(2), 227–29.
Baggiolini, M., Dewald, B., & Moser, B. (1997). Human chemokines: An update. Annual Review of Immunology, 15, 675–05.
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., & Kasper, J., et al. (1995). The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. Journal of Biological Chemistry, 270(45), 27348–7357.
Strieter, R. M., Burdick, M. D., Mestas, J., Gomperts, B., Keane, M. P., & Belperio, J. A. (2006). Cancer CXC chemokine networks and tumour angiogenesis. European Journal of Cancer, 42(6), 768–78.
Belperio, J. A., Keane, M. P., Arenberg, D. A., Addison, C. L., Ehlert, J. E., & Burdick, M. D., et al. (2000). CXC chemokines in angiogenesis. Journal of Leukocyte Biology, 68(1), 1–.
Luster, A. D. (1998). Chemokines’chemotactic cytokines that mediate inflammation. New England Journal of Medicine, 338(7), 436–45.
Strieter, R. M., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., & Polverini, P. J. (1995). Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochemical and Biophysical Research Communications, 210(1), 51–7.
Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., & Bauer, S. I., et al. (1990). Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science, 247(4938), 77–9.
Nagpal, M. L., Chen, Y., & Lin, T. (2004). Effects of overexpression of CXCL10 (cytokine-responsive gene-2) on MA-10 mouse Leydig tumor cell steroidogenesis and proliferation. Journal of Endocrinology, 183(3), 585–94.
Nagasawa, T., Nakajima, T., Tachibana, K., Iizasa, H., Bleul, C. C., & Yoshie, O., et al. (1996). Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proceedings of the National Academy of Sciences of the United States of America, 93(25), 14726–4729.
Mirshahi, F., Pourtau, J., Li, H., Muraine, M., Trochon, V., & Legrand, E., et al. (2000). SDF-1 activity on microvascular endothelial cells: Consequences on angiogenesis in in vitro and in vivo models. Thrombosis Research, 99(6), 587–94.
Orimo, A., Gupta, P. B., Sgroi, D. C., renzana-Seisdedos, F., Delaunay, T., & Naeem, R., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121(3), 335–48.
Salcedo, R., Wasserman, K., Young, H. A., Grimm, M. C., Howard, O. M., & Anver, M. R., et al. (1999). Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. American Journal of Pathology, 154(4), 1125–135.
Tachibana, K., Hirota, S., Iizasa, H., Yoshida, H., Kawabata, K., & Kataoka, Y., et al. (1998). The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature, 393(6685), 591–94.
Baggiolini, M., Dewald, B., & Moser, B. (1994). Interleukin-8 and related chemotactic cytokines’CXC and CC chemokines. Advances in Immunology, 55, 97–79.
Bischoff, S. C., Krieger, M., Brunner, T., Rot, A., von, T. V., & Baggiolini, M., et al. (1993). RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors. European Journal of Immunology, 23(3), 761–67.
Dahinden, C. A., Geiser, T., Brunner, T., von, T. V., Caput, D., & Ferrara, P., et al. (1994). Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. Journal of Experimental Medicine, 179(2), 751–56.
Garcia-Zepeda, E. A., Rothenberg, M. E., Ownbey, R. T., Celestin, J., Leder, P., & Luster, A. D. (1996). Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nature Medicine, 2(4), 449–56.
Imai, T., Yoshida, T., Baba, M., Nishimura, M., Kakizaki, M., & Yoshie, O. (1996). Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. Journal of Biological Chemistry, 271(35), 21514–1521.
Jose, P. J., Griffiths-Johnson, D. A., Collins, P. D., Walsh, D. T., Moqbel, R., & Totty, N. F., et al. (1994). Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. Journal of Experimental Medicine, 179(3), 881–87.
Kameyoshi, Y., Dorschner, A., Mallet, A. I., Christophers, E., & Schroder, J. M. (1992). Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. Journal of Experimental Medicine, 176(2), 587–92.
Ponath, P. D., Qin, S., Ringler, D. J., Clark-Lewis, I., Wang, J., & Kassam, N., et al. (1996). Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. Journal of Clinical Investigation, 97(3), 604–12.
Rot, A., Krieger, M., Brunner, T., Bischoff, S. C., Schall, T. J., & Dahinden, C. A. (1992). RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. Journal of Experimental Medicine, 176(6), 1489–495.
Kelner, G. S., Kennedy, J., Bacon, K. B., Kleyensteuber, S., Largaespada, D. A., & Jenkins, N. A., et al. (1994). Lymphotactin: A cytokine that represents a new class of chemokine. Science, 266(5189), 1395–399.
Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., & Rossi, D., et al. (1997). A new class of membrane-bound chemokine with a CX3C motif. Nature, 385(6617), 640–44.
Segerer, S., Hughes, E., Hudkins, K. L., Mack, M., Goodpaster, T., & Alpers, C. E. (2002). Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney International, 62(2), 488–95.
Umehara, H., & Imai, T. (2001). Role of fractalkine in leukocyte adhesion and migration and in vascular injury. Drug News & Perspectives, 14(8), 460–64.
Pan, Y., Lloyd, C., Zhou, H., Dolich, S., Deeds, J., & Gonzalo, J. A., et al. (1997). Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature, 387(6633), 611–17.
Thelen, M. (2001). Dancing to the tune of chemokines. Nature Immunology, 2(2), 129–34.
Lee, J., Horuk, R., Rice, G. C., Bennett, G. L., Camerato, T., & Wood, W. I. (1992). Characterization of two high affinity human interleukin-8 receptors. Journal of Biological Chemistry, 267(23), 16283–6287.
Wuyts, A., Proost, P., Lenaerts, J. P., Ben-Baruch, A., Van, D. J., & Wang, J. M. (1998). Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78. European Journal of Biochemistry, 255(1), 67–3.
Baggiolini, M., & Loetscher, P. (2000). Chemokines in inflammation and immunity. Immunology Today, 21(9), 418–20.
Locati, M., & Murphy, P. M. (1999). Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annual Review of Medicine, 50, 425–40.
Cole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., & Gladue, R. P., et al. (1998). Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. Journal of Experimental Medicine, 187(12), 2009–021.
Farber, J. M. (1997). Mig and IP-10: CXC chemokines that target lymphocytes. Journal of Leukocyte Biology, 61(3), 246–57.
Loetscher, M., Loetscher, P., Brass, N., Meese, E., & Moser, B. (1998). Lymphocyte-specific chemokine receptor CXCR3: Regulation, chemokine binding and gene localization. European Journal of Immunology, 28(11), 3696–05.
Feng, Y., Broder, C. C., Kennedy, P. E., & Berger, E. A. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 272(5263), 872–77.
Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J. L., & renzana-Seisdedos, F., et al. (1996). The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature, 382(6594), 833–35.
Legler, D. F., Loetscher, M., Roos, R. S., Clark-Lewis, I., Baggiolini, M., & Moser, B. (1998). B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. Journal of Experimental Medicine, 187(4), 655–60.
Deng, H. K., Unutmaz, D., KewalRamani, V. N., & Littman, D. R. (1997). Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature, 388(6639), 296–00.
Matloubian, M., David, A., Engel, S., Ryan, J. E., & Cyster, J. G. (2000). A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nature Immunology, 1(4), 298–04.
Berkhout, T. A., Gohil, J., Gonzalez, P., Nicols, C. L., Moores, K. E., & Macphee, C. H., et al. (2000). Selective binding of the truncated form of the chemokine CKbeta8 (25–9) to CC chemokine receptor 1(CCR1). Biochemical Pharmacology, 59(5), 591–96.
Gong, J. H., Uguccioni, M., Dewald, B., Baggiolini, M., & Clark-Lewis, I. (1996). RANTES and MCP-3 antagonists bind multiple chemokine receptors. Journal of Biological Chemistry, 271(18), 10521–0527.
Hwang, J., Son, K. N., Kim, C. W., Ko, J., Na, D. S., & Kwon, B. S., et al. (2005). Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis. Cytokine, 30(5), 254–63.
Neote, K., Darbonne, W., Ogez, J., Horuk, R., & Schall, T. J. (1993). Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. Journal of Biological Chemistry, 268(17), 12247–2249.
Tsou, C. L., Gladue, R. P., Carroll, L. A., Paradis, T., Boyd, J. G., & Nelson, R. T., et al. (1998). Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor. Journal of Experimental Medicine, 188(3), 603–08.
Charo, I. F., Myers, S. J., Herman, A., Franci, C., Connolly, A. J., & Coughlin, S. R. (1994). Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proceedings of the National Academy of Sciences of the United States of America, 91(7), 2752–756.
Moore, U. M., Kaplow, J. M., Pleass, R. D., Castro, S. W., Naik, K., & Lynch, C. N., et al. (1997). Monocyte chemoattractant protein-2 is a potent agonist of CCR2B. Journal of Leukocyte Biology, 62(6), 911–15.
Stellato, C., Collins, P., Ponath, P. D., Soler, D., Newman, W., & La, R. G., et al. (1997). Production of the novel C-C chemokine MCP-4 by airway cells and comparison of its biological activity to other C-C chemokines. Journal of Clinical Investigation, 99(5), 926–36.
Forssmann, U., Uguccioni, M., Loetscher, P., Dahinden, C. A., Langen, H., & Thelen, M., et al. (1997). Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. Journal of Experimental Medicine, 185(12), 2171–176.
Forssmann, U., Hartung, I., Balder, R., Fuchs, B., Escher, S. E., & Spodsberg, N., et al. (2004). n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation. Journal of Immunology, 173(5), 3456–466.
Uguccioni, M., Mackay, C. R., Ochensberger, B., Loetscher, P., Rhis, S., & LaRosa, G. J., et al. (1997). High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. Journal of Clinical Investigation, 100(5), 1137–143.
Youn, B. S., Zhang, S. M., Lee, E. K., Park, D. H., Broxmeyer, H. E., & Murphy, P. M., et al. (1997). Molecular cloning of leukotactin-1: a novel human beta-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. Journal of Immunology, 159(11), 5201–205.
Imai, T., Baba, M., Nishimura, M., Kakizaki, M., Takagi, S., & Yoshie, O. (1997). The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. Journal of Biological Chemistry, 272(23), 15036–5042.
Imai, T., Chantry, D., Raport, C. J., Wood, C. L., Nishimura, M., & Godiska, R., et al. (1998). Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. Journal of Biological Chemistry, 273(3), 1764–768.
Littman, D. R. (1998). Chemokine receptors: Keys to AIDS pathogenesis. Cell, 93(5), 677–80.
Blanpain, C., Migeotte, I., Lee, B., Vakili, J., Doranz, B. J., & Govaerts, C., et al. (1999). CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood, 94(6), 1899–905.
Baba, M., Imai, T., Nishimura, M., Kakizaki, M., Takagi, S., & Hieshima, K., et al. (1997). Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. Journal of Biological Chemistry, 272(23), 14893–4898.
Yoshida, R., Imai, T., Hieshima, K., Kusuda, J., Baba, M., & Kitaura, M., et al. (1997). Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. Journal of Biological Chemistry, 272(21), 13803–3809.
Tiffany, H. L., Lautens, L. L., Gao, J. L., Pease, J., Locati, M., & Combadiere, C., et al. (1997). Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309. Journal of Experimental Medicine, 186(1), 165–70.
Zaballos, A., Gutierrez, J., Varona, R., Ardavin, C., & Marquez, G. (1999). Cutting edge: Identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. Journal of Immunology, 162(10), 5671–675.
Bonini, J. A., & Steiner, D. F. (1997). Molecular cloning and expression of a novel rat CC-chemokine receptor (rCCR10rR) that binds MCP-1 and MIP-1beta with high affinity. DNA and Cell Biology, 16(9), 1023–030.
Wang, W., Soto, H., Oldham, E. R., Buchanan, M. E., Homey, B., & Catron, D., et al. (2000). Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2). Journal of Biological Chemistry, 275(29), 22313–2323.
Mantovani, A. (1999). The chemokine system: redundancy for robust outputs. Immunology Today, 20(6), 254–57.
Folkman, J., & Cotran, R. (1976). Relation of vascular proliferation to tumor growth. International Review of Experimental Pathology, 16, 207–48.
Folkman, J. (1985). Tumor angiogenesis. Advances in Cancer Research, 43, 175–03.
Folkman, J., & Klagsbrun, M. (1987). Vascular physiology. A family of angiogenic peptides. Nature, 329(6141), 671–72.
Leibovich, S. J., & Wiseman, D. M. (1988). Macrophages, wound repair and angiogenesis. Progress in Clinical and Biological Research, 266, 131–45.
Strieter, R. M., Belperio, J. A., Phillips, R. J., & Keane, M. P. (2004). CXC chemokines in angiogenesis of cancer. Seminars in Cancer Biology, 14(3), 195–00.
Hu, D. E., Hori, Y., & Fan, T. P. (1993). Interleukin-8 stimulates angiogenesis in rats. Inflammation, 17(2), 135–43.
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., & Elner, V. M., et al. (1992). Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science, 258(5089), 1798–801.
Norrby, K. (1996). Interleukin-8 and de novo mammalian angiogenesis. Cell Proliferation, 29(6), 315–23.
Strieter, R. M., Kunkel, S. L., Elner, V. M., Martonyi, C. L., Koch, A. E., & Polverini, P. J., et al. (1992). Interleukin-8. A corneal factor that induces neovascularization. American Journal of Pathology, 141(6), 1279–284.
Yoshida, S., Ono, M., Shono, T., Izumi, H., Ishibashi, T., & Suzuki, H., et al. (1997). Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Molecular and Cellular Biology, 17(7), 4015–023.
Li, A., Dubey, S., Varney, M. L., Dave, B. J., & Singh, R. K. (2003). IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. Journal of Immunology, 170(6), 3369–376.
Shono, T., Ono, M., Izumi, H., Jimi, S. I., Matsushima, K., & Okamoto, T., et al. (1996). Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Molecular and Cellular Biology, 16(8), 4231–239.
Li, A., Varney, M. L., Valasek, J., Godfrey, M., Dave, B. J., & Singh, R. K. (2005). Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis, 8(1), 63–1.
Inoue, K., Slaton, J. W., Eve, B. Y., Kim, S. J., Perrotte, P., & Balbay, M. D., et al. (2000). Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clinical Cancer Research, 6(5), 2104–119.
Luca, M., Huang, S., Gershenwald, J. E., Singh, R. K., Reich, R., & Bar-Eli, M. (1997). Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. American Journal of Pathology, 151(4), 1105–113.
McCawley, L. J., & Matrisian, L. M. (2000). Matrix metalloproteinases: multifunctional contributors to tumor progression. Molecular Medicine Today, 6(4), 149–56.
Xie, K. (2001). Interleukin-8 and human cancer biology. Cytokine and Growth Factor Reviews, 12(4), 375–91.
Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D., & Fidler, I. J. (1998). Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. Journal of the National Cancer Institute, 90(6), 447–54.
Benoy, I. H., Salgado, R., Van, D. P., Geboers, K., Van, M. E., & Scharpe, S., et al. (2004). Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clinical Cancer Research, 10(21), 7157–162.
Veltri, R. W., Miller, M. C., Zhao, G., Ng, A., Marley, G. M., & Wright Jr., G. L., et al. (1999). Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology, 53(1), 139–47.
Aalinkeel, R., Nair, M. P., Sufrin, G., Mahajan, S. D., Chadha, K. C., & Chawda, R. P., et al. (2004). Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Research, 64(15), 5311–321.
Lehrer, S., Diamond, E. J., Mamkine, B., Stone, N. N., & Stock, R. G. (2004). Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technology in Cancer Research and Treatment, 3(5), 411.
Uehara, H., Troncoso, P., Johnston, D., Bucana, C. D., Dinney, C., & Dong, Z., et al. (2005). Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate, 64(1), 40–9.
Murdoch, C., Monk, P. N., & Finn, A. (1999). Cxc chemokine receptor expression on human endothelial cells. Cytokine, 11(9), 704–12.
Salcedo, R., Resau, J. H., Halverson, D., Hudson, E. A., Dambach, M., & Powell, D., et al. (2000). Differential expression and responsiveness of chemokine receptors (CXCR1–) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB Journal 2000, 14(13), 2055–064.
Addison, C. L., Daniel, T. O., Burdick, M. D., Liu, H., Ehlert, J. E., & Xue, Y. Y., et al. (2000). The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. Journal of Immunology, 165(9), 5269–277.
Keane, M. P., Belperio, J. A., Xue, Y. Y., Burdick, M. D., & Strieter, R. M. (2004). Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. Journal of Immunology, 172(5), 2853–860.
Mestas, J., Burdick, M. D., Reckamp, K., Pantuck, A., Figlin, R. A., & Strieter, R. M. (2005). The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. Journal of Immunology, 175(8), 5351–357.
Numasaki, M., Watanabe, M., Suzuki, T., Takahashi, H., Nakamura, A., & McAllister, F., et al. (2005). IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. Journal of Immunology, 175(9), 6177–189.
Arenberg, D. A., Keane, M. P., DiGiovine, B., Kunkel, S. L., Morris, S. B., & Xue, Y. Y., et al. (1998). Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. Journal of Clinical Investigation, 102(3), 465–72.
Kanda, S., Mochizuki, Y., & Kanetake, H. (2003). Stromal cell-derived factor-1alpha induces tube-like structure formation of endothelial cells through phosphoinositide 3-kinase. Journal of Biological Chemistry, 278(1), 257–62.
Neuhaus, T., Stier, S., Totzke, G., Gruenewald, E., Fronhoffs, S., & Sachinidis, A., et al. (2003). Stromal cell-derived factor 1alpha (SDF-1alpha) induces gene-expression of early growth response-1 (Egr-1) and VEGF in human arterial endothelial cells and enhances VEGF induced cell proliferation. Cell Proliferation, 36(2), 75–6.
Salcedo, R., & Oppenheim, J. J. (2003). Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation, 10(3–), 359–70.
Guleng, B., Tateishi, K., Ohta, M., Kanai, F., Jazag, A., & Ijichi, H., et al. (2005). Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Research, 65(13), 5864–871.
Barbero, S., Bonavia, R., Bajetto, A., Porcile, C., Pirani, P., & Ravetti, J. L., et al. (2003). Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Research, 63(8), 1969–974.
Phillips, R. J., Burdick, M. D., Lutz, M., Belperio, J. A., Keane, M. P., & Strieter, R. M. (2003). The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. American Journal of Respiratory and Critical Care Medicine, 167(12), 1676–686.
Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Morris, S. B., Burdick, M. D., & Glass, M. C., et al. (1996). Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. Journal of Experimental Medicine, 184(3), 981–92.
Sgadari, C., Angiolillo, A. L., Cherney, B. W., Pike, S. E., Farber, J. M., & Koniaris, L. G., et al. (1996). Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 93(24), 13791–3796.
Sgadari, C., Farber, J. M., Angiolillo, A. L., Liao, F., Teruya-Feldstein, J., & Burd, P. R., et al. (1997). Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood, 89(8), 2635–643.
Dorsey, R., Kundu, N., Yang, Q., Tannenbaum, C. S., Sun, H., & Hamilton, T. A., et al. (2002). Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Research, 62(9), 2606–610.
Ruehlmann, J. M., Xiang, R., Niethammer, A. G., Ba, Y., Pertl, U., & Dolman, C. S., et al. (2001). MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Research, 61(23), 8498–503.
Kondo, T., Ito, F., Nakazawa, H., Horita, S., Osaka, Y., & Toma, H. (2004). High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. Journal of Urology, 171(6 Pt 1), 2171–175.
Romagnani, P., Annunziato, F., Lasagni, L., Lazzeri, E., Beltrame, C., & Francalanci, M., et al. (2001). Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. Journal of Clinical Investigation, 107(1), 53–3.
Nagpal, M. L., Davis, J., & Lin, T. (2006). Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochimica et Biophysica Acta, 1762(9), 811–18.
Salcedo, R., Ponce, M. L., Young, H. A., Wasserman, K., Ward, J. M., & Kleinman, H. K., et al. (2000). Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression. Blood, 96(1), 34–0.
Hong, K. H., Ryu, J., & Han, K. H. (2005). Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood, 105(4), 1405–407.
Goede, V., Brogelli, L., Ziche, M., & Augustin, H. G. (1999). Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. International Journal of Cancer, 82(5), 765–70.
Leung, S. Y., Wong, M. P., Chung, L. P., Chan, A. S., & Yuen, S. T. (1997). Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathologica (Berlin), 93(5), 518–27.
Blaschke, S., Koziolek, M., Schwarz, A., Benohr, P., Middel, P., & Schwarz, G., et al. (2003). Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. Journal of Rheumatology, 30(9), 1918–927.
Nanki, T., Urasaki, Y., Imai, T., Nishimura, M., Muramoto, K., & Kubota, T., et al. (2004). Inhibition of fractalkine ameliorates murine collagen-induced arthritis. Journal of Immunology, 173(11), 7010–016.
Volin, M. V., Woods, J. M., Amin, M. A., Connors, M. A., Harlow, L. A., & Koch, A. E. (2001). Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. American journal of Pathology, 159(4), 1521–530.
Combadiere, C., Potteaux, S., Gao, J. L., Esposito, B., Casanova, S., & Lee, E. J., et al. (2003). Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation, 107(7), 1009–016.
Eriksson, E. E. (2004). Mechanisms of leukocyte recruitment to atherosclerotic lesions: Future prospects. Current Opinion in Lipidology, 15(5), 553–58.
Umehara, H., Goda, S., Imai, T., Nagano, Y., Minami, Y., & Tanaka, Y., et al. (2001). Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunology and Cell Biology, 79(3), 298–02.
Lee, S. J., Namkoong, S., Kim, Y. M., Kim, C. K., Lee, H., & Ha, K. S., et al. (2006). Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. American Journal of Physiology, Heart and Circulatory Physiology, 291(6), H2836’H2846.
Singh, R. K., & Fidler, I. J. (1996). Regulation of tumor angiogenesis by organ-specific cytokines. In U. Gunthert, & W. Birchmeier (Eds.) Attempts to understand metastasis formation II (pp. 1–1). New York: Springer.
Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine, 1(1), 27–1.
Keane, M. P., Arenberg, D. A., Lynch III, J. P., Whyte, R. I., Iannettoni, M. D., & Burdick, M. D., et al. (1997). The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. Journal of Immunology, 159(3), 1437–443.
Arenberg, D. A., Polverini, P. J., Kunkel, S. L., Shanafelt, A., Hesselgesser, J., & Horuk, R., et al. (1997). The role of CXC chemokines in the regulation of angiogenesis in non- small cell lung cancer. Journal of Leukocyte Biology, 62(5), 554–62.
Fidler, I. J. (1995). Cancer biology: Invasion and metastasis. New York: Churchill Livingstone.
Fidler, I. J., & Ellis, L. M. (1994). The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79, 185–88.
Nicolson, G. L. (1991). Tumor and host molecules important in the organ preference of metastasis. Seminars in Cancer Biology, 2(3), 143–54.
Fidler, I. J., Singh, R. K., Yoneda, J., Kumar, R., Xu, L., & Dong, Z., et al. (2000). Critical determinants of neoplastic angiogenesis. Cancer Journal from Scientific American, 6(Suppl 3), S225’S236.
Balkwill, F. (2003). Chemokine biology in cancer. Seminars in Immunology, 15(1), 49–5.
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., & Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50–6.
Murphy, P. M. (2001). Chemokines and the molecular basis of cancer metastasis. New England Journal of Medicine, 345(11), 833–35.
Fidler, I. J. (2002). The organ microenvironment and cancer metastasis. Differentiation, 70(9–0), 498–05.
Nakamura, E. S., Koizumi, K., Kobayashi, M., Saitoh, Y., Arita, Y., & Nakayama, T., et al. (2006). RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clinical and Experimental Metastasis, 23(1), 9–8.
Balkwill, F. (2004). Cancer and the chemokine network. Nature Reviews Cancer, 4(7), 540–50.
Cabioglu, N., Yazici, M. S., Arun, B., Broglio, K. R., Hortobagyi, G. N., & Price, J. E., et al. (2005). CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clinical Cancer Research, 11(16), 5686–693.
Hao, L., Zhang, C., Qiu, Y., Wang, L., Luo, Y., & Jin, M., et al. (2007). Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Letters, 253, 34–2.
Smith, M. C., Luker, K. E., Garbow, J. R., Prior, J. L., Jackson, E., & Piwnica-Worms, D., et al. (2004). CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Research, 64(23), 8604–612.
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., & Huang, H., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6(1), 17–2.
Saur, D., Seidler, B., Schneider, G., Algul, H., Beck, R., & Senekowitsch-Schmidtke, R., et al. (2005). CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology, 129(4), 1237–250.
Wehler, T., Wolfert, F., Schimanski, C. C., Gockel, I., Herr, W., & Biesterfeld, S., et al. (2006). Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncology Reports, 16(6), 1159–164.
Scotton, C. J., Wilson, J. L., Scott, K., Stamp, G., Wilbanks, G. D., & Fricker, S., et al. (2002). Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Research, 62(20), 5930–938.
Burger, M., Glodek, A., Hartmann, T., Schmitt-Graff, A., Silberstein, L. E., & Fujii, N., et al. (2003). Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene, 22(50), 8093–101.
Pan, J., Mestas, J., Burdick, M. D., Phillips, R. J., Thomas, G. V., & Reckamp, K., et al. (2006). Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Molecular Cancer, 5, 56.
Kaifi, J. T., Yekebas, E. F., Schurr, P., Obonyo, D., Wachowiak, R., & Busch, P., et al. (2005). Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. Journal of the National Cancer Institute, 97(24), 1840–847.
Scala, S., Ottaiano, A., Ascierto, P. A., Cavalli, M., Simeone, E., & Giuliano, P., et al. (2005). Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clinical Cancer Research, 11(5), 1835–841.
Arya, M., Patel, H. R., McGurk, C., Tatoud, R., Klocker, H., & Masters, J., et al. (2004). The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. Journal of Experimental Therapeutics and Oncology, 4(4), 291–03.
Schimanski, C. C., Schwald, S., Simiantonaki, N., Jayasinghe, C., Gonner, U., & Wilsberg, V., et al. (2005). Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clinical Cancer Research, 11(5), 1743–750.
Su, L., Zhang, J., Xu, H., Wang, Y., Chu, Y., & Liu, R., et al. (2005). Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clinical Cancer Research, 11(23), 8273–280.
Hu, J., Deng, X., Bian, X., Li, G., Tong, Y., & Li, Y., et al. (2005). The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma. Clinical Cancer Research, 11(13), 4658–665.
Laverdiere, C., Hoang, B. H., Yang, R., Sowers, R., Qin, J., & Meyers, P. A., et al. (2005). Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clinical Cancer Research, 11(7), 2561–567.
Kim, J., Takeuchi, H., Lam, S. T., Turner, R. R., Wang, H. J., & Kuo, C., et al. (2005). Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. Journal of Clinical Oncology, 23(12), 2744–753.
Airoldi, I., Raffaghello, L., Piovan, E., Cocco, C., Carlini, B., & Amadori, A., et al. (2006). CXCL12 does not attract CXCR4 + human metastatic neuroblastoma cells: clinical implications. Clinical Cancer Research, 12(1), 77–2.
Weigelt, B., Wessels, L. F., Bosma, A. J., Glas, A. M., Nuyten, D. S., & He, Y. D., et al. (2005). No common denominator for breast cancer lymph node metastasis. British Journal of Cancer, 93(8), 924–32.
Ivarsson, K., Ekerydh, A., Fyhr, I. M., Janson, P. O., & Brannstrom, M. (2000). Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas. Acta Obstetricia et Gynecologica Scandinavica, 79(9), 777–84.
Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Glass, M., Burdick, M. D., & Strieter, R. M. (1996). Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. Journal of Clinical Investigation, 97(12), 2792–802.
Varney, M. L., Johansson, S. L., & Singh, R. K. (2006). Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. American Journal of Clinical Pathology, 125(2), 209–16.
Grimm, M. C., Elsbury, S. K., Pavli, P., & Doe, W. F. (1996). Interleukin 8: cells of origin in inflammatory bowel disease. Gut, 38(1), 90–8.
Nurnberg, W., Tobias, D., Otto, F., Henz, B. M., & Schadendorf, D. (1999). Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. Journal of Pathology, 189(4), 546–51.
Scheibenbogen, C., Mohler, T., Haefele, J., Hunstein, W., & Keilholz, U. (1995). Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Research, 5(3), 179–81.
Singh, R. K., Gutman, M., Radinsky, R., Bucana, C. D., & Fidler, I. J. (1994). Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Research, 54(12), 3242–247.
Ugurel, S., Rappl, G., Tilgen, W., & Reinhold, U. (2001). Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. Journal of Clinical Oncology, 19(2), 577–83.
Ding, Y., Shimada, Y., Maeda, M., Kawabe, A., Kaganoi, J., & Komoto, I., et al. (2003). Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clinical Cancer Research, 9(9), 3406–412.
Gunther, K., Leier, J., Henning, G., Dimmler, A., Weissbach, R., & Hohenberger, W., et al. (2005). Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. International Journal of Cancer, 116(5), 726–33.
Mashino, K., Sadanaga, N., Yamaguchi, H., Tanaka, F., Ohta, M., & Shibuta, K., et al. (2002). Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Research, 62(10), 2937–941.
Takanami, I. (2003). Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. International Journal of Cancer, 105(2), 186–89.
Wang, J., Xi, L., Gooding, W., Godfrey, T. E., & Ferris, R. L. (2005). Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. Advances in Oto-rhino-laryngology, 62, 121–3.
Takeuchi, H., Fujimoto, A., Tanaka, M., Yamano, T., Hsueh, E., & Hoon, D. S. (2004). CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clinical Cancer Research, 10(7), 2351–358.
Wiley, H. E., Gonzalez, E. B., Maki, W., Wu, M. T., & Hwang, S. T. (2001). Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. Journal of the National Cancer Institute, 93(21), 1638–643.
Sancho, M., Vieira, J. M., Casalou, C., Mesquita, M., Pereira, T., & Cavaco, B. M., et al. (2006). Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. Journal of Endocrinology, 191(1), 229–38.
Tsuzuki, H., Takahashi, N., Kojima, A., Narita, N., Sunaga, H., & Takabayashi, T., et al. (2006). Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. Auris Nasus Larynx, 33(1), 37–2.
Craig, M. J., & Loberg, R. D. (2006). CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer and Metastasis Reviews, 25(4), 611–119.
Lu, Y., Cai, Z., Galson, D. L., Xiao, G., Liu, Y., & George, D. E., et al. (2006). Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate, 66(12), 1311–318.
Johrer, K., Zelle-Rieser, C., Perathoner, A., Moser, P., Hager, M., & Ramoner, R., et al. (2005). Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clinical Cancer Research, 11(7), 2459–465.
Harasawa, H., Yamada, Y., Hieshima, K., Jin, Z., Nakayama, T., & Yoshie, O., et al. (2006). Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma. Leukaemia and Lymphoma, 47(10), 2163–173.
Vaday, G. G., Peehl, D. M., Kadam, P. A., & Lawrence, D. M. (2006). Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate, 66(2), 124–34.
Ghadjar, P., Coupland, S. E., Na, I. K., Noutsias, M., Letsch, A., & Stroux, A., et al. (2006). Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. Journal of Clinical Oncology, 24(12), 1910–916.
Letsch, A., Keilholz, U., Schadendorf, D., Assfalg, G., Asemissen, A. M., & Thiel, E., et al. (2004). Functional CCR9 expression is associated with small intestinal metastasis. Journal of Investigative Dermatology, 122(3), 685–90.
Singh, S., Singh, U. P., Stiles, J. K., Grizzle, W. E., & Lillard Jr. , J. W. (2004). Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clinical Cancer Research, 10(24), 8743–750.
Simonetti, O., Goteri, G., Lucarini, G., Filosa, A., Pieramici, T., & Rubini, C., et al. (2006). Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. European Journal of Cancer, 42(8), 1181–187.
Meijer, J., Zeelenberg, I. S., Sipos, B., & Roos, E. (2006). The CXCR5 Chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Research, 66(19), 9576–582.
Shulby, S. A., Dolloff, N. G., Stearns, M. E., Meucci, O., & Fatatis, A. (2004). CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Research, 64(14), 4693–698.
Kawada, K., Sonoshita, M., Sakashita, H., Takabayashi, A., Yamaoka, Y., & Manabe, T., et al. (2004). Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Research, 64(11), 4010–017.
Pellegrino, A., Antonaci, F., Russo, F., Merchionne, F., Ribatti, D., & Vacca, A., et al. (2004). CXCR3-binding chemokines in multiple myeloma. Cancer Letters, 207(2), 221–27.
Soejima, K., & Rollins, B. J. (2001). A functional IFN-gamma-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. Journal of Immunology, 167(11), 6576–582.
Goldberg-Bittman, L., Neumark, E., Sagi-Assif, O., Azenshtein, E., Meshel, T., & Witz, I. P., et al. (2004). The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunology Letters, 92(1–), 171–78.
Longo-Imedio, M. I., Longo, N., Trevino, I., Lazaro, P., & Sanchez-Mateos, P. (2005). Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. International Journal of Cancer, 117(5), 861–65.
Suyama, T., Furuya, M., Nishiyama, M., Kasuya, Y., Kimura, S., & Ichikawa, T., et al. (2005). Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer, 103(2), 258–67.
Kawada, K., Hosogi, H., Sonoshita, M., Sakashita, H., Manabe, T., & Shimahara, Y., et al. (2007). Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene, 26, 4679–688
Dutt, P., Wang, J. F., & Groopman, J. E. (1998). Stromal cell-derived factor-1 alpha and stem cell factor/kit ligand share signaling pathways in hemopoietic progenitors: a potential mechanism for cooperative induction of chemotaxis. Journal of Immunology, 161(7), 3652–658.
Ganju, R. K., Brubaker, S. A., Meyer, J., Dutt, P., Yang, Y., & Qin, S., et al. (1998). The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. Journal of Biological Chemistry, 273(36), 23169–3175.
Mellado, M., Rodriguez-Frade, J. M., Aragay, A., del, R. G., Martin, A. M., & Vila-Coro, A. J., et al. (1998). The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. Journal of Immunology, 161(2), 805–13.
Takami, M., Terry, V., & Petruzzelli, L. (2002). Signaling pathways involved in IL-8-dependent activation of adhesion through Mac-1. Journal of Immunology, 168(9), 4559–566.
Gutkind, J. S. (1998). The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. Journal of Biological Chemistry, 273(4), 1839–842.
Gutkind, J. S. (1998). Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene, 17(11 Reviews), 1331–342.
Schraufstatter, I. U., Chung, J., & Burger, M. (2001). IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. American Journal of Physiology, Lung Cellular and Molecular Physiology, 280(6), L1094’L1103.
Jordan, J. D., Landau, E. M., & Iyengar, R. (2000). Signaling networks: the origins of cellular multitasking. Cell, 103(2), 193–00.
Singh, R. K., Gutman, M., Radinsky, R., Bucana, C. D., & Fidler, I. J. (1994). Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Research, 54(12), 3242–247.
Schadendorf, D., Moller, A., Algermissen, B., Worm, M., Sticherling, M., & Czarnetzki, B. M. (1993). IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor [published erratum appears in J Immunol 1994 Oct 1;153(7):3360]. Journal of Immunology, 151(5), 2667–675.
Varney, M. L., Li, A., Dave, B. J., Johansson, S. L., Bucana C. B., & Singh, R. K. (2003). Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotypes. Clinical and Experimental Metastasis, 20, 723–31
Luca, M., Huang, S., Gershenwald, J. E., Singh, R. K., Reich, R., & Bar-Eli, M. (1997). Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. American Journal of Pathology, 151(4), 1105–113.
Singh, R. K., Gutman, M., Reich, R., & Bar-Eli, M. (1995). Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Research, 55(16), 3669–674.
Li, A., Dubey, S., Varney, M. L., & Singh, R. K. (2002). Interleukin-8-induced proliferation, survival, and MMP production in CXCR1 and CXCR2 expressing human umbilical vein endothelial cells. Microvascular Research, 64(3), 476–81.
Wang, J. M., Taraboletti, G., Matsushima, K., Van Damme, J., & Mantovani, A. (1990). Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochemical and Biophysical Research Communications, 169(1), 165–70.
Wang, J. M., Deng, X., Gong, W., & Su, S. (1998). Chemokines and their role in tumor growth and metastasis. Journal of Immunological Methods, 220(1–), 1–7.
Singh, R. K., Varney, M. L., Bucana, C. D., & Johansson, S. L. (1999). Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Research, 9(4), 383–87.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, S., Sadanandam, A. & Singh, R.K. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 26, 453–467 (2007). https://doi.org/10.1007/s10555-007-9068-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-007-9068-9